CompletedPhase 1NCT00397384

Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer

Studying Carcinoma of liver and intrahepatic biliary tract

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Laura Goff
Vanderbilt-Ingram Cancer Center
Intervention
cetuximab(drug)
Enrollment
43 enrolled
Eligibility
18 years · All sexes
Timeline
20072013

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00397384 on ClinicalTrials.gov

Other trials for Carcinoma of liver and intrahepatic biliary tract

Additional recruiting or active studies for the same condition.

See all trials for Carcinoma of liver and intrahepatic biliary tract

← Back to all trials